neffy, epinephrine nasal spray, Demonstrates a Positive Efficacy and Safety Profile for the Treatment of Allergic Reactions in Pediatric Patients at-Risk of Anaphylaxis: Phase 3 Study Results

被引：0

作者：

Ebisawa, Motohiro ^{[1
]}

Lowenthal, Richard ^{[2
]}

Tanimoto, Sarina ^{[3
]}

Takahashi, Kento ^{[4
]}

Takahashi, Kyohei Kyohei ^{[4
]}

Yanagida, Noriyuki ^{[4
]}

Sato, Sakura ^{[4
]}

机构：

[1] Sagamihara Natl Hosp, Sagamihara, Japan

[2] ARS Pharmaceut, San Diego, CA USA

[3] ARS Pharmaceut Inc, San Diego, CA USA

[4] NHO Sagamihara Natl Hosp, Sagamihara, Japan

来源：

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY | 2024年 / 153卷 / 02期

关键词：

D O I：

暂无

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

L33

引用

页码：AB371 / AB371

页数：1

共 50 条

[21] Efficacy, safety of adalimumab versus methotrexate in pediatric patients with severe chronic plaque psoriasis: Results from the treatment withdrawal and double-blind retreatment periods of a phase 3 study
Phillip, Sandra
Pierre-Dominique, Pierre-Dominique
Landells, Ian
Unnebrink, Kristina
Williams, David A.
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S16 - S16
[22] Efficacy and Safety of Pegcetacoplan Treatment in Complement-Inhibitor Naive Patients with Paroxysmal Nocturnal Hemoglobinuria: Results from the Phase 3 Prince Study
Wong, Raymond S.
Navarro, Juan Ramon
Comia, Narcisa Sonia
Goh, Yeow Tee
Idrobo, Henry
Kongkabpan, Daolada
Gomez-Almaguer, David
Al-Adhami, Mohammed
Ajayi, Temitayo
Alvarenga, Paulo
Deschatelets, Pascal
Francois, Cedric
Grossi, Federico
Dumagay, Teresita
BLOOD, 2021, 138
[23] Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/ Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study
Bartlett, Nancy L.
Sehn, Laurie H.
Matasar, Matthew J.
Schuster, Stephen J.
Assouline, Sarit E.
Giri, Pratyush
Kuruvilla, John
Canales, Miguel
Dietrich, Sascha
Fay, Keith
Ku, Matthew
Nastoupil, Loretta
Wei, Michael C.
Yin Shen
To, Iris
Huang Huang
Min, Juliana
Bolen, Christopher R.
Penuel, Eliciaand
Elizabeth, Budde L.
AMERICAN JOURNAL OF HEMATOLOGY, 2023, 98 : S44 - S44
[24] Mosunetuzumab Monotherapy Demonstrates Durable Efficacy With a Manageable Safety Profile in Patients With Relapsed/Refractory Follicular Lymphoma who Received ≥2 Prior Therapies: Updated Results From a Pivotal Phase II Study
Bartlett, Nancy L.
Sehn, Laurie H.
Matasar, Matthew
Schuster, Stephen J.
Assouline, Sarit
Giri, Pratyush
Kuruvilla, John
Canales, Miguel
Dietrich, Sascha
Fay, Keith
Ku, Matthew
Nastoupil, Loretta
Wei, Michael C.
Yin, Shen
To, Iris
Huang, Huang
Min, Juliana
Bolen, Christopher R.
Penuel, Elicia
Budde, L. Elizabeth
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S453 - S453
[25] Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study
Bartlett, Nancy L.
Sehn, Laurie H.
Matasar, Matthew J.
Schuster, Stephen J.
Assouline, Sarit
Giri, Pratyush
Kuruvilla, John
Canales, Miguel
Dietrich, Sascha
Fay, Keith
Ku, Matthew
Nastoupil, Loretta J.
Wei, Michael C.
Yin, Shen
To, Iris
Huang, Huang
Min, Juliana
Penuel, Elicia
Budde, L. Elizabeth
BLOOD, 2022, 140 : 1467 - 1470
[26] Mosunetuzumab monotherapy demonstrates durable efficacy with a manageable safety profile in patients with relapsed/ refractory follicular lymphoma who received ≥2 prior therapies: updated results from a pivotal Phase II study
Dietrich, S.
Bartlett, N. L.
Sehn, L. H.
Matasar, M.
Schuster, S. J.
Assouline, S.
Giri, P.
Kuruvilla, J.
Canales, M.
Fay, K.
Ku, M.
Nastoupil, L.
Wie, M. C.
Yin, S.
To, I.
Huang, H.
Min, J.
Bolen, C. R.
Penuel, E.
Budde, L. E.
ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 211 - 212
[27] Final results from a Phase 3, long-term, open-label, repeat-dose safety study of diazepam nasal spray for seizure clusters in patients with epilepsy
Wheless, James W.
Miller, Ian
Hogan, R. Edward
Dlugos, Dennis
Biton, Victor
Cascino, Gregory D.
Sperling, Michael R.
Liow, Kore
Vazquez, Blanca
Segal, Eric B.
Tarquinio, Daniel
Mauney, Weldon
Desai, Jay
Rabinowicz, Adrian L.
Carrazana, Enrique
EPILEPSIA, 2021, 62 (10) : 2485 - 2495
[28] A PHASE 3 STUDY OF TENOFOVIR ALAFENAMIDE COMPARED WITH TENOFOVIR DISOPROXIL FUMARATE IN PATIENTS WITH HBEAG-POSITIVE CHRONIC HBV: WEEK 48 EFFICACY AND SAFETY RESULTS
Chan, H. L. Y.
Fung, S.
Seto, W. K.
Chuang, W. -L.
Chen, C. -Y.
Kim, H. J.
Hui, A. J.
Janssen, H. L. A.
Chowdhury, A.
Tsang, T. Y. O.
Mehta, R.
Gane, E.
Flaherty, J. F.
Massetto, B.
Kitrinos, K.
Dinh, P.
Subramanian, G. M.
McHutchison, J. G.
Lim, Y. -S.
Acharya, S. K.
Agarwal, K.
JOURNAL OF HEPATOLOGY, 2016, 64 : S161 - S161
[29] Secukinumab demonstrates high efficacy and a favourable safety profile in paediatric patients with severe chronic plaque psoriasis: 52-week results from a Phase 3 double-blind randomized, controlled trial
Bodemer, C.
Kaszuba, A.
Kingo, K.
Tsianakas, A.
Morita, A.
Rivas, E.
Papanastasiou, P.
Keefe, D.
Patekar, M.
Charef, P.
Zhang, L.
Cafoncelli, S.
Papavassilis, C.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2021, 35 (04) : 938 - 947
[30] Do Patients With Lennox-Gastaut Syndrome Respond Differently to Diazepam Nasal Spray (Valtoco®) Than Other Patients with Pediatric Encephalopathies? Final Safety and Effectiveness Results From a Phase 3, Long-Term Open-Label, Repeat-Dose Safety Study
Tarquinio, D.
Wheless, J.
Segal, E.
Misra, S.
Rabinowicz, A.
Carrazana, E.
ANNALS OF NEUROLOGY, 2022, 92 : S73 - S75

← 1 2 3 4 5 →